Phase II Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Oral Agent in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Nov 2011 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 21 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.